Podcasts about Breakwater

Los Dres. Isabel Enríquez, Fernando Aldaco y Homero Fuentes, oncólogos médicos mexicanos, comparten su análisis de los estudios más relevantes presentados durante el primer y segundo día de la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica, celebrada en Chicago, con base en la información disponible al momento de esta grabación.Los trabajos comentados son:BREAKWATER (abstract #LBA3500)CheckMate 8HW (abstract #3501)CodeBreaK 300 (abstract #3540)Abstract #1014Abstract #1015INAVO120 (abstract #1003)DYNAMIC-III (abstract #3503)VERITAC-2 (abstract #LBA1000)ASCENT-04/KEYNOTE-D19 (abstract #LBA109)C-POST (abstract #6001)Fuentes:Abstracts presentados en el marco de la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO®) de 2025, Chicago, IL, EE.UU.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados. ASCO® es una marca registrada de la American Society of Clinical Oncology. Este material ha sido producido de manera independiente y no está autorizado, patrocinado ni avalado por dicha organización.

**Lynda Law's Soul Show Replay On traxfm.org. This Week Lynda Features Soul/Boogie/Dance Classics/Contemporary Soul From Herbie Hancock, Breakwater, Meco, T-Connection, Bruno Mars, Bernard Edwards, Quincy Jones, Stevie Woods, Cameron, Bobby Thurston, The Whispers & More #originalpirates #soulmusic #contemporarysoul #70smusic #80smusic #disco #danceclassics Catch Lynda's Soul Show Every Tuesday From 4:00PM UK Time On www.traxfm.org Listen Live Here Via The Trax FM Player: chat.traxfm.org/player/index.html Mixcloud LIVE :mixcloud.com/live/traxfm Free Trax FM Android App: play.google.com/store/apps/det...mradio.ba.a6bcb The Trax FM Facebook Page : https://www.facebook.com/profile.php?id=100092342916738 Trax FM Live On Hear This: hearthis.at/k8bdngt4/live Tunerr: tunerr.co/radio/Trax-FM Radio Garden: Trax FM Link: http://radio.garden/listen/trax-fm/IEnsCj55 OnLine Radio Box: onlineradiobox.com/uk/trax/?cs...cs=uk.traxRadio Radio Deck: radiodeck.com/radio/5a09e2de87...7e3370db06d44dc Radio.Net: traxfmlondon.radio.net Stream Radio : streema.com/radios/Trax_FM..The_Originals Live Online Radio: liveonlineradio.net/english/tr...ax-fm-103-3.htm**

From Club Space to Regatta Grove, Emi Guerra has seen it all. We trace his journey from hustling in high school as a club promoter to launching iconic venues like Club Space, The Wharf, and Regatta Grove. Emi opens up about the rollercoaster ride of entrepreneurship — the early struggles, near-collapse, and the eventual rise of Breakwater Hospitality.It's a raw, insightful look at what it takes to build Miami's most memorable nightlife and hospitality experiences and a powerful reminder that you don't fail until you quit.Connect with usWant to dive deeper into Miami's commercial real estate scene? It's our favorite topic—and we're always up for a good conversation. Whether you're just exploring or already making big moves, feel free to reach out at felipe@builtworldadvisors.com or give us a call at 305.498.9410. Prefer to connect online? Find us on LinkedIn or Instagram—we're always open to expanding the conversation. Ben Hoffman: LinkedIn Felipe Azenha: LinkedIn We extend our sincere gratitude to Büro coworking space for generously granting us the opportunity to record all our podcasts at any of their 8 convenient locations across South Florida.

Send us a textWelcome to The Oncology Journal Club Podcast Series 3! Proudly produced by The Oncology NetworkThree respected oncologists dive deep into the most significant research presented at ASCO GI 2025, bringing you practice-changing insights amidst a backdrop of political uncertainty affecting medical research.Professor Chris Karapetis joins hosts Professor Craig Underhill and Professor Christopher Jackson to unpack ground-breaking colorectal cancer studies that are reshaping treatment paradigms. The conversation explores how targeted therapies are dramatically improving survival rates, with the DEEPER study demonstrating cetuximab's superiority over bevacizumab for left-sided RAS wild-type disease, achieving an impressive 50-month median survival when combined with chemotherapy.The experts dissect the BREAKWATER trial, which shows promising benefits of combining encorafenib and cetuximab with chemotherapy for notoriously aggressive BRAF-mutant colorectal cancer. This combination achieved a 61% response rate versus 40% with standard care, with responses lasting significantly longer – representing a potential new standard of care for this difficult-to-treat subgroup.Perhaps most surprisingly, our panel discusses how an inexpensive, familiar medication – aspirin – could reduce colorectal cancer recurrence by 40% in patients with PIK3CA mutations according to the ALASCCA study. This finding highlights how molecular profiling is becoming essential across treatment stages, not just for expensive targeted therapies but also for optimising use of accessible interventions.The discussion extends to exciting developments in pancreatic cancer with a novel pan-RAS inhibitor showing meaningful activity, and advancements in immunotherapy for MSI-high colorectal cancer, confirming combination therapy's superiority. For gastrointestinal oncologists navigating an increasingly complex treatment landscape, this episode offers crucial insights to optimise patient outcomes through precise, personalised approaches.Subscribe to The Oncology Newsletter for regular updates on the latest cancer research and join our community at oncologynetwork.com.au.The Oncology Podcast - An Australian Oncology Perspective

Surging seas and boulders regularly cut off people living on Trepassey's lower road. The town's brand new breakwater was swept away last year... and since then residents feel adrift. We reach the mayor of Trepassey to hear about the breakwater problems... and unkept promises. (Krissy Holmes with Rita Pennell)

Katie Jaegly from UW Extension joins the podcast to share some of her experiences and what she does and also her involvement with Substance Free Futures.

**The Groove Doctors Friday Drive Time Show Replay On traxfm.org. This Week The Groove Doctor Featured 80's Grooves/Rare Groove/Contemporary Soul From Selection Of Tracks From Merry Clayton. Breakwater. Harvey Mason. M.C.B. Jean Carne. William C Brown lll. The Pointer Sisters. Randy Brown. Little Beaver. Freddie Hubbard. Numonics & More #originalpirates #soulmusic #boogie #80ssoul #RareGrooves Listen Live Here Via The Trax FM Player: chat.traxfm.org/player/index.html Mixcloud LIVE :mixcloud.com/live/traxfm Free Trax FM Android App: play.google.com/store/apps/det...mradio.ba.a6bcb The Trax FM Facebook Page : facebook.com/profile.php?id=10...100092342916738 Trax FM Live On Hear This: hearthis.at/k8bdngt4/live Tunerr: tunerr.co/radio/Trax-FM Radio Garden: Trax FM Link: radio.garden/listen/trax-fm/IEnsCj55 OnLine Radio Box: onlineradiobox.com/uk/trax/?cs...cs=uk.traxRadio Radio Deck: radiodeck.com/radio/5a09e2de87...7e3370db06d44dc Radio.Net: traxfmlondon.radio.net Stream Radio : streema.com/radios/Trax_FM..The_Originals Live Online Radio: liveonlineradio.net/english/tr...ax-fm-103-3.htm**

Dr. Shaalan Beg and Dr. David Wang discuss key abstracts in GI cancers from the 2025 ASCO Gastrointestinal Cancers Symposium, including major advances in CRC, neoadjuvant approaches in esophageal cancer, and innovative studies on ctDNA. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas. Today, we're bringing you some key highlights from the 2025 ASCO Gastrointestinal Cancers Symposium, and I'm delighted to be joined by the chair of GI25, Dr. David Wang. Dr. Wang is a GI medical oncologist at the University of Michigan. Our full disclosures are available in the transcript of this episode.  Dr. Wang, thanks for coming on the podcast today. Dr. David Wang: Well, thank you. It's a pleasure to be here. Dr. Shaalan Beg: GI25 featured major therapeutic advances across the spectrum of GI malignancies, and it was exciting to hear about innovations and novel approaches that are shaping the future of our field. Before we start talking about specific abstracts, could you share some of your key highlights from the meeting? Dr. David Wang: Sure. Our theme this year was “Breaking Boundaries to Enhance Patient Centered Care.” Past years' themes have focused more on precision oncology, but we wanted to broaden our focus on patients and to be more holistic, which kind of led us into some of the Intersection [sessions] that we had. Each day started with a different Intersection. The first one was “Emerging Therapies in GI Cancers”, where invited speakers talked about bispecific antibody drug conjugates, theranostics, CAR T and other cell-based therapies. The second day was on “Personalized Risk Assessment for GI Cancers,” and this included looking at polygenic risk scores for colorectal cancer, microRNAs and liquid biopsies such as exosomes and pancreatic cancer and non-endoscopic screening modalities in esophageal cancer. And on our final day, we wanted to talk about “Integrative Oncology and Integrative Medicine,” looking at evidence-based uses of acupuncture and supplements in patients who are receiving treatment for cancer, mindfulness-based practices and exercise. And of course, we had a fantastic keynote talk by Dr. Pamela Kunz from the Yale School of Medicine titled, “Disrupting Gastrointestinal Oncology: Shattering Barriers with Inclusive Science.” She highlighted the intersection of science, patient care, and health and gender equity. And I would encourage your podcast listeners to access the lecture in ASCO's Meeting Library if they haven't yet had a chance to hear Dr. Kunz's wonderful lecture.  We were really happy this year because the attendance hit a new record. We had over 5,000 people attend either in person or virtually from their home or office, and we had almost 1,000 abstracts submitted to the meeting, so these were either record or near record numbers. We offered a lot of different networking opportunities throughout the meeting, and attending found these to be incredibly rewarding and important and this will continue to be an area of emphasis in future meetings. Dr. Shaalan Beg: Let's take a deeper dive into the exciting studies presented at GI25. The late breaking abstract LBA143 was CheckMate-8HW. This was the first results of NIVO + IPI versus NIVO monotherapy for MSI-high metastatic colorectal cancer. What are your thoughts about this study? Dr. David Wang: Yeah, so we know that colorectal cancer patients with MSI-high tumors don't necessarily respond well to chemotherapy. And we were fortunate because last year CheckMate-8HW actually looked at two different arms – so this was NIVO + IPI compared to standard of care chemotherapy and showed its very significant improvement in median progression-free survival. And that was actually published in the New England Journal of Medicine back in November of 2024. This year's presentation actually focused now on NIVO + IPI versus NIVO monotherapy. And as you know IPI+NIVO can be quite toxic. So this was an important analysis to be done. So we know that NIVO is definitely more easily tolerated. So what was interesting was that the 2-year and 3-year progression-free survival not surprisingly favored IPI+NIVO and this was statistically significant. And the overall response rate was also better with IPI+NIVO versus NIVO alone. I know we're always concerned about toxicities and there were higher grade 3 and 4 toxicity incidences in the combination arm versus the monotherapy arm, but overall, only about 28 additional events in several hundred patients treated. So I think that's well-tolerated. Our discussant Dr. Wells Messersmith actually said that, with this new data, he would consider doing combination immunotherapy in any patient that presented in the front line with MSI-high or deficient mismatch repair colorectal cancer that was metastatic. Dr. Shaalan Beg: One of the focuses for directing first-line therapy for colorectal cancer has been right and left sided colon cancer because we know these are two different cancers with their own unique molecular subtypes. We heard on Abstract 17, the DEEPER trial, the final analysis of modified FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left sided metastatic colorectal cancer. How do you summarize the findings of this study and what should our readers be aware of? Dr. David Wang: Interestingly, this was a phase 2 study and the emphasis of the abstract was actually a subgroup analysis of those patients with RAS wild-type and BRAF wild-type as well as left sided cancers. So, I think the entire study enrolled 359 patients, but the analysis that was discussed at the meeting really focused on 178 patients that fit that characteristic. Very similar to what we've seen in prior studies, left-sided tumors have better response to cetuximab versus bevacizumab. And if you flip it so that you now are looking at right sided tumors, targeting EGFR is actually detrimental. The depth of response was better with cetuximab in these left sided RAS and BRAF mutant tumors. And so the lead author actually suggested that this could be a new first-line standard of care. And the question is, is there a benefit of doing this triple agent regimen with modified FOLFIRINOX? We know there's a lot more toxicity with that. Not clear that there's a benefit for that over FOLFOX, maybe in younger patients that could tolerate it. When our discussant, again Dr. Wells Messersmith, spoke about this, he said that, in his practice he would, again, favor cetuximab over bevacizumab in combination with chemo, these left-sided RAS and BRAF wild-type tumors, but that he would actually prefer a doublet versus a triplet chemo regimen, and that is consistent with the current NCCN guidelines. Dr. Shaalan Beg: Another area where colorectal cancer has been a wonderful model to study new technology has been in the area of circulating tumor DNA (ctDNA). And the BESPOKE CRC trial is looking to see if ctDNA can inform adjuvant treatment decisions for stage II and III colorectal cancer. And in Abstract 15, we heard final results of the BESPOKE CRC sub-cohort. What were the findings there? Dr. David Wang: BESPOKE CRC is another one of these important ctDNA studies. It was an observational study, not a randomized trial, but it did provide a lot of different insights to us. We know that there were over 1,700 patients enrolled, and so it was reported that this is the largest ctDNA study in colorectal cancer performed in the United States. And they were able to analyze over 1,100 patients.  Some of the key findings were that postoperative adjuvant therapy management decisions actually changed in 1 out of 6 patients, so that's pretty significant. In terms of surveillance, we know that patients who have ctDNA positivity, this is prognostic of recurrence. In terms of patients who have positive ctDNA post-surgery, it looked like, at least in this observational study, the majority of patients who received any benefit were those who had positive ctDNA. So adjuvant therapy, even in stage II and stage III patients seemed to only benefit those patients who have positive ctDNA. I think that does raise the question, and this also was brought up in the discussion, which is “Can we de-escalate adjuvant therapy in terms of patients who are ctDNA-negative post-op?” And Dr. Richard Kim from Moffitt felt that we are not yet there. Obviously, we need randomized control trials where we are taking ctDNA results and then randomizing patients to receive adjuvant or non-adjuvant to really know the difference.  Other questions that come up with use of ctDNA include: What do you do with these patients who turn positive? This study for BESPOKE actually followed patients out to two years after surgery. So what you do with a positive ctDNA result wasn't really clear. It seems to suggest that once you turn positive, patients go on to more intensive surveillance. You know, again as an observation, patients who did turn positive were able to go to metastasis-directed therapy much more quickly. And again, this was supposedly to improve their curative intent therapy. And I think the other question that has been brought up all the time is, is this really cost effective? Patients want to know, and we want to give patients that information, but I think we're still stuck with what to do with a positive ctDNA level in a patient that's on surveillance because no randomized control studies have actually suggested that we need to start systemic therapy right away. Dr. Shaalan Beg: Yeah. And I guess in terms of practice informing or practice changing, these results may not give us a clear answer. But because a lot of patients are asking for these tests, it does give us some real world experiences on what to expect in terms of conversion of these positive into negative and the outcome so we can have a shared decision making with our patients in the clinic and then come up with a determination on whether ctDNA for molecular residual disease is something which would be worthwhile for the care of our patient. But more to come, I guess, in coming years to answer different problems around this challenge. Dr. David Wang: Yes, I agree. Dr. Shaalan Beg: The BREAKWATER trial looked at the use of encorafenib, cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer. We've covered this combination for a second- third-line treatment in metastatic colorectal cancer previously. Abstract 16 from GI25 was evaluating the use of this regimen in the first-line space. Everyone was looking forward to these results, and what did the investigators present? Dr. David Wang: I think this is, as you mentioned, a nice follow up to later lines of therapy where Dr. Kopetz from MD Anderson pioneered use of encorafenib, cetuximab and binimetinib in the BEACON trial. Everybody was kind of curious what would happen now if you use encorafenib plus cetuximab plus chemotherapy in the first-line setting. And so this is an interim analysis that was pre-planned in the phase 3 open label BREAKWATER trial. And even though there were three arms, and so the three arms were encorafenib plus cetuximab, encorafenib plus cetuximab plus FOLFOX, or standard of care chemo, only two arms were presented in the abstract. So basically looking at encorafenib plus cetuximab and FOLFOX-6 versus standard of care therapy, and the overall response rate was statistically significant with a 60.9% overall response rate encorafenib plus cetuximab plus chemo arm versus standard of care chemo was only 40%. The interim overall survival also was different. It was 92% versus 87% at 6 months and 79% versus 66% at 12 months, again favoring the chemotherapy plus encorafenib plus cetuximab. In terms of the statistics, the p was 0.0004. However, the pre-plan analysis required the p-value to be 1x10 to the -8. And so even though this looks really good, it hasn't quite met its pre-specified significance level. The good thing is that this is only interim analysis and the study is ongoing with future analysis planned.  So the real question is: Does it matter when we actually use this regimen? We know that the regimen's approved in the second third-line setting. What about in the first line? And there was some preclinical data that the discussant reviewed that shows that patients actually benefit if this is done in the first-line setting. For example, there was some preclinical data showing that even FOLFIRI, for example, can upregulate RAS, which would make tumors more resistant to this combination. This was thought to be practice-changing in a patient that has B600E showing up treatment naive that we should probably consider this regimen. And actually this did receive accelerated FDA approval about a month ago. Dr. Shaalan Beg: Yeah, and for what it's worth, I put up a Twitter poll asking my Twitter followers on how the BREAKWATER trial results will change their approach for newly diagnosed BRAF mutated colorectal cancer. We got 112 responses; 72% said that they will incorporate encorafenib, cetuximab, FOLFOX for their frontline BRAF mutated patients. But 23% said that they would like to wait for overall survival results. Dr. David Wang: Wow, that's interesting. They really want that 1x10 to the -8. Dr. Shaalan Beg: I guess so. All right. Let's change gears and talk about esophageal cancer. LBA329 was the SCIENCE study which presented preliminary results from a randomized phase 3 trial comparing sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant resectable locally advanced squamous esophageal cancer. Where are we in this space? Dr. David Wang: Okay. So, yeah, this was an interesting trial. Again, just to set the context, esophageal squamous cell carcinoma is more prevalent in Asia. And the study sites as well as the patients were mostly from Asia. So this was again a phase 3 trial with interim results. They only rolled 146 out of the planned 420 for this interim analysis. And yeah, they're using immune checkpoint inhibitor that we don't use in the United States, sintilimab, combined with their two standards of neoadjuvant therapy, either chemotherapy, which is more common in Asia, or or chemoradiation, which is more common in the US and Western Europe, versus chemoradiation. And so they actually had two primary endpoints, but only were reporting one. So their two primary endpoints were pathCR and the other one was event-free survival. The event-free survival, again, was not reported at the meeting.  What they found was that in terms of pathCR rate, if you take the two arms that are really informative about that, chemoradiation plus sintilimab versus chemoradiation alone, the pathCR rate was 60% versus 47%. We know that chemo alone doesn't induce as much of a pathCR rate, and that was 13%. So it was found that the delta in terms of pathCR between the chemoradiation arms, one with sintilimab and one without, was significant. And this actually confirms data again from Asia, like for the ESCORT-NEO trial where it used another immune checkpoint inhibitor pembrolizumab in addition to neoadjuvant chemo.  So as our discussant for this abstract said, yes, we know that radiation combined with chemotherapy improves pathCR rates, but we have recent data from the ESOPEC trial, we don't know that that necessarily will translate to overall survival. So again, waiting for additional enrollments and longer term follow up before incorporating this into clinical care here. Dr. Shaalan Beg: So David, how do the results of the SCIENCE trial compare with our practice in the United States and ongoing studies asking questions for neoadjuvant therapy for esophageal carcinoma in the United States? Dr. David Wang: I think obviously immune checkpoint inhibitor in the new adjuvant setting is important. Jennifer Eads at UPenn is running that EA2174 which is looking at chemoradiation plus or minus nivolumab, and then in non-pathCR responders randomized to adjuvant nivolumab per CheckMate 577 or nivolumab with intensification adding ipilimumab. We know that the ESOPEC trial just came out, and was published actually during the meeting, and that really focuses on adenocarcinomas. So adenocarcinomas of the GE junction, distal esophagus, now, we would probably treat very similarly to gastric using perioperative FLOT. However, the standard in the US for esophageal squamous cell carcinoma remains neoadjuvant chemoradiation. We know that squamous cell carcinomas are more exquisitely sensitive to radiotherapy. And then obviously in those patients who don't achieve a pathologic complete response, the expectation would be that they would go on to receive nivolumab per CheckMate 577. Again, the thought is that these tumors are more sensitive to immunotherapy given their higher incidences of mutational changes. And so again, this kind of goes along with the positive results seen in the SCIENCE trial that we just discussed with sintilimab but also EFFECT-neo with pembrolizumab. Obviously, we await the results of Jennifer's trial. Dr. Shaalan Beg: And the last abstract I was hoping we could get your perspective on was Abstract 652, which is a Phase 3 study of everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors, the STARTER-NET trial. What were the results of this study? Dr. David Wang: So, I just want to give a shout out because we did have a session at this year's GI ASCO that looked at more rare tumors. So appendiceal tumors, neuroendocrine tumors, those kinds of things. So again, I would encourage your listeners to listen to that session if they have interest in that. Another type of rare tumor was adenosquamous tumors.  But in terms of the STARTER-NET trial, this was again an interim analysis of his phase 3trial and it was looking at combining everolimus plus lanreotide versus everolimus. So we know that in pancreatic-gastric neuroendocrine tumors, if you have low Ki-67, a well differentiated tumor, that the standard of care really is a somatostatin analog, and sometimes if they're more aggressive, we kind of consider molecular targeted therapy with everolimus. This was asking the question of whether we should do the combination on the frontline. And what was interesting is in this study, the patients were actually more of a poor prognostic set. So they had Ki-67 up to 20% or these were patients that actually had multiple liver lesions. And what they found was a median for progression free survival was improved with a combination out to 29.7 months versus 11.5 months with the somatostatin analog alone, and that the overall response rate was 23% versus 8.3%, again, favoring the combination. If you looked at subgroup analysis, it was actually those patients who had Ki-67 greater than 10%, so the more aggressive tumors, or those with diffuse liver lesions that had the most benefit. So I think that would be the patient population I would consider this new combination with using would be those patients again with poorer prognosis neuroendocrine tumor phenotype. Dr. Shaalan Beg: Thank you very much, Dr. Wang, for sharing your insights with us today and your great work to build a robust GI Cancers Symposium this year. Dr. David Wang: Well, thank you. I mean that really is a cooperative effort. We appreciate all the members of the GI25 Program Committee as well as the ASCO staff that just made it an outstanding meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. David Wang Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Dr. David Wang: Honoraria:  Novartis Consulting or Advisory Role: Novartis, Cardinal Health, Bristol-Myers Squibb, BeiGene, Eisai  

I've got the Estuary Tour Save the date and the BW Exchange Germany Flyer attached as PDF's and have the links for the RSVP and Exchange ticket website below: Estuary Tour RSVP: Estuary Tour RSVP https://docs.google.com/forms/d/e/1FAIpQLSeB3ffRphBA8QH844v6K0KdcyaDnRfeX9IF-9zZGpFZixNIQA/ Breakwater Exchange Germany Ticket Page: Buy tickets – Breakwater  https://www.tickettailor.com/events/breakwater/1518547  Exchange - Deutschland 2025 – Wird bald bekanntgegeben Let me know if that will work for you. If you like you can also provide the BW email as well: contact.breakwater@gmail.com   Christ and Culture event Saturday Feb 15 2025 Galway Ireland https://www.eventbrite.ie/e/christ-and-culture-tickets-1104448638609    Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/KEPbZT28 https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://calendly.com/paulvanderklay/one2one There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640 https://www.livingstonescrc.com/give  

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Alok Khorana, a GI medical oncologist from the Cleveland Clinic, to discuss the latest highlights from the GI ASCO 2025 conference. We dive into four key studies that are practice-informing and potentially practice-changing: 1. BREAKWATER: We explore the implications of using Encorafenib and Cetuximab in combination with FOLFOX for patients with BRAF V600E mutations, which are associated with poor prognosis. 2. CheckMate-8HW: This study investigates whether dual checkpoint inhibition is more effective than single-agent immunotherapy for MSI-high patients, revealing promising results in progression-free survival. 3. Aspirin in Adjuvant Settings: We discuss the role of low-dose aspirin in reducing recurrence rates for patients with PI3K alterations, highlighting its potential as a practice-changing intervention. 4. STARTER-NET: Finally, we review the findings from the study on Everolimus combined with Lanreotide for neuroendocrine tumors, noting the lack of overall survival benefit. Tune in for an insightful discussion on these important topics in oncology, and learn how these findings could impact treatment strategies in your practice. Don't forget to like, subscribe, and check out our other episodes for more conference highlights and treatment discussions! YouTube: https://youtu.be/YOToz3hKYTg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers #OncologyBrothers #GIASCO2025 #ColorectalCancer #Immunotherapy #NeuroendocrineTumors #CancerResearch #Podcast

We discuss recent approvals of ensartinib and nivolumab-hyaluronidase as well as new front-line option for BRAV-V600E mutated metastatic colorectal cancer.

Lead Time listeners, Tim Ahlman here! We love bringing you content to grow as leaders in your ministry and beyond, but we want to make sure we're hitting the mark. Can you help us out by filling out a quick 5-question survey? It'll take less than a minute and help us know what you like about the podcast, what topics you want more of, and even which guests you'd love to hear from next.https://www.surveymonkey.com/r/LeadTimePodcastThe episode highlights the innovative ministry of Pastor Ed Doerner, who shows how churches can effectively engage communities by addressing what they need help with! Through initiatives like a car repair garage and grocery store, Pastor Ed illustrates the importance of dignity and sustainable models in outreach, encouraging churches to expand their missions beyond conventional practices. • Pastor Ed Doerner's journey of innovative ministry • Addressing transportation challenges through affordable car repairs • The impact of running a grocery store on community dignity • Importance of serving the ALICE population in ministry • Engaging the community through volunteerism and participation • The eight core needs of communities: housing, transportation, food, childcare, jobs, healthcare, recovery, and community • Trusting in God's provision when stepping beyond comfort zones • Encouragement for churches to embrace missional outreach strategiesSupport the showJoin the Lead Time Newsletter! (Weekly Updates and Upcoming Episodes)https://www.uniteleadership.org/lead-time-podcast#newsletterVisit uniteleadership.org

Every new author has things to learn, but there are some major mistakes early on that some make over and over again. Eight authors reveal them so that you can avoid making them yourself!Featuring, from Engen Books:Matthew Daniels, author of InterstichesJRH Lawless, author of Always Greener From Flanker Press:Ida Linehan Young, author of A Secret Close to Home From Breakwater Books:Paul David Power, author of CrippledDr Richard Elcock, contributor to Us, NowMichelle Porter, author of Approaching FireOlivia Robinson, author of The Blue Moth Motel, and more!Originally broadcast on December 2, 2024 on CHMR 93.5 FM in St. John's, and on other great stations across the country. Check out As Loved Our Fathers, the latest book from Write Project host Matthew LeDrew: https://amzn.to/3HB7BABIt's a hunt for the Holy Grail taken on by an American Anthropologist and a Newfoundland History professor that unveils hidden secrets within Newfoundland history! Support the showProduced and recorded at CHMR 93.5 FM in St. John's, Newfoundland. Listen on CHMR online at http://www.chmr.ca/​This program is sponsored by:Engen Books: Checkout Engen titles at http://www.engenbooks.com/​Or sign up for their newsletters at: The Write Project signup for FREE book: http://eepurl.com/c8W9OTEngen Horror Society Signup for FREE book: http://eepurl.com/c8YemrFantasy Files signup for FREE book: http://eepurl.com/c8X4zLEngen's Science-Fiction Newsletter for FREE book: http://eepurl.com/ir5JmgThis recording copyright © 2024 Matthew LeDrew

Manitowoc North Breakwater Lighthouse, USLHS photo by Tom Tag The city of Manitowoc, Wisconsin, is on the west shore of Lake Michigan, at the mouth of the Manitowoc River. The Manitowoc North Breakwater Lighthouse, built in 1918, is one of the area's most familiar icons. The lighthouse property was auctioned by the federal government in 2010 under the guidelines of the National Historic Lighthouse Preservation Act. The buyer was Philip Carlucci of Melville, New York. Courtesy of the Manitowoc Sunrise Rotary Club Since he's owned the lighthouse, Phil Carlucci has been responsible for much restoration. He has now partnered with the Manitowoc Sunrise Rotary Club to offer public tours of the lighthouse. Members of the club keep the building clean and offer tours on a regular basis. Interviewed in this podcast episode are three board members of the Manitowoc Sunrise Rotary Club:  Paul Roekle, Dennis Huckins, and Mike Woznick. Manitowoc North Breakwater Lighthouse soon after it was constructed (National Archives)

HERE WE GO MY SHOW FOR 14-NOV-2024 WITH A MIXED BAG OF OLD CLASSICS INCLUDING ( EARTH WIND & FIRE, WEBSTER LEWIS, JUICY, DENNIS EDWARDS, JEAN CARN, BREAKWATER, STEVIE WONDER, MELBA MOORE  ) AND MANY MORE ALSO SOME TOP NEW TRACKS FROM ( LOUISE MEHAN/KATHY KOSINS, JULIAN JONAH/ROBBY LOVE, MATHER ) WE ALSO HAVE THE CONNOISSEURS CORNER ( THIS WEEK WE HAVE  TRACKS FROM HIROSHI FUKUMURA AND B BAKER CHOCOLATE CO  ) AND WE HAVE THE BACK TO BACK CLASSICS BY A CLASSIC ARTIST (THIS WEEK WE HAVE TWO TRACKS FROM PHYLLIS HYMAN ) THEN WE HAVE THREE TRACKS DUG OUT FROM THE GARAGE FROM MARVIN GAY & TAMMI TERRELL TWO SONGS , MARVIN GAY & KIM WESTON ) FINNISHING OF WITH A COUPLE OF SLOW TRACKS AND MUCH MUCH MORE SIT BACK WITH A GLASS OF SOMETHING AND ENJOY OR DOWNLOAD FOR LATER

Businesses operating in and identifying with the 2SLGBTQIA+ community are making a difference in the Chamber of Commerce movement across Canada. In this Chamber Chat CEO Bruce Williams engages with the Canadian 2SLGBTQIA+ Chamber CEO and a local queer business owner for a conversation about how this inclusion makes a difference.

In this episode, Avery Hill Publishing's Ricky Miller talks to Katriona about the cultural influences on her work in comics. Kat picks a favourite book, play, film, comic, and TV show to discuss. The post Signals From The Hill #59 – Katriona Chapman (author of ‘Breakwater' and ‘Follow Me In') about the cultural influences on her work in comics appeared first on Avery Hill Publishing.

Learn about the new wave of Breakwater a youth substance use prevention coalition.

Today on Art of the Cut, we discuss Michael B. Jordan's directorial debut, Creed III, with the editors of the film, Jessica Baclesse and Tyler Nelson, ACE. Jessica is currently editing the film Rez Ball. She was an assistant editor on Captain Marvel, has edited numerous short films, and the TV series, Breakwater, Play By Play and In the Vault. Her commercial editing work has been nominated for numerous awards. Tyler  has been on Art of the Cut several times, including for his work as an editor on The Batman and the TV series Mindhunter. He also edited TV series including Love, Death and Robots, Shadow and Bone and Tales from the Loop. As an assistant editor, he worked on Gone Girl and The Social Network and the TV series House of Cards. If you want to read along with the podcast and see some great exclusive images and clips from the movie, check out the Art of the Cut blog on BorisFX at: borisfx.com/blog/AOTC.

Racine County boasts a diverse landscape of cities, villages, and towns, offering a blend of urban and rural experiences. In this episode, we delve into the rich history and Danish heritage of Racine, home to the renowned O&H Danish Bakery, and explore its active arts community and educational initiatives, such as the Ardagh Glass Company's partnership with Burlington's STEM program. Recognized for its vibrant downtown scene, Racine has earned accolades for events like First Fridays and the Party on the Pavement, while Burlington hosts the lively Jamboree and Experience Burlington Days. Outdoor enthusiasts can revel in the natural beauty of Lake Michigan at North Beach and partake in activities like the Aquaducks water skiing show at Brown's Lake. Additionally, the county offers a plethora of recreational amenities, from parks like Jonathan - Pritchard Park to attractions like the Racine Zoo and dining establishments ranging from Well Brothers Pizza to Fred's Burgers. Economic development initiatives, such as the Microsoft Data Center and Breakwater 233, underscore the county's commitment to growth and prosperity.Learn more about Racine County here:Racine County: https://bit.ly/4aCHlBFExplore Burlington: https://bit.ly/4550P0zRacine Downtown: https://bit.ly/4dQTbeeVisit Racine County: https://bit.ly/4azmGP3Explore Waterford:https://bit.ly/4aJIoQiSponsored By: Racine County: https://bit.ly/4aCHlBF

For IROs, it is more important than ever to understand strategic trajectory, market position, and risk management for their companies. In today's episode, Mark Fasken sits down with Mark Hayes, Partner and Head of Capital Markets Advisory at Breakwater Strategy, to discuss the evolving role of the elevated IRO, the significance of collaboration across functions for effective IR. and how IR can use impact intelligence to customize approaches and gather relevant insights for decision-making and valuation. Listen to the full episode to learn more about:Defining the Elevated IROThe six essential skills of an Elevated IROIdentifying skill gaps and opportunitiesAn introduction to impact intelligence and it's impact and use casesNext steps for Elevated IROsWinning IR is brought to you by Irwin. For more winning ideas, subscribe to Winning IR wherever you get your podcasts.For more information, visit getirwin.com/winning-ir

https://buttickets.at/breakwater/1242831 https://tinyurl.com/BreakwaterDiscord breakwater@gmail.com   July 5 to 7 Leusden, The Netherlands   Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/JpHtVgXW https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://calendly.com/paulvanderklay/one2one There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Introducing Jake from Vive 18 – an exciting opportunity to discover the latest initiatives in our community focusing on drug prevention for young teens. Tune in to hear about the incredible advancements and impactful movements spearheaded by our youth! Get ready to be inspired!

Rhys Laverty writes about the Alderney Breakwater, a crumbling jetty in the Channel Islands that protects a way of life.

In this episode Nataraj talked to Peter Mueller who is the founding partner of Breakwater ventures investing in early stage tech startups in Pacific Northwest and Wester Canadian Startups. The conversation includes: - how to think about angel investing & pre-seed investing? - Seattle pre-seed ecosystem - learnings from Seachange fund - thesis for breakwater - Whats making Western Canada an interesting place to invest? - investing in AI - long tail opportunity in AI & more. Follow peter on twitter here - https://twitter.com/pjsmueller Follow Nataraj on twitter here - https://twitter.com/natarajsindam Follow 100 Days of AI here - https://thestartupproject.io/100-days-of-ai/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/startupproject/message

On a blustery day, Canadian - and even more geographically specific - Victoria author Jean Paetkau talks about her book "Blood on the Breakwater". Paetkau reveals the title of her upcoming sequel is "The Sinking of Souls" with a storyline that also is based locally. To be released in September 2024 you will find it on Amazon and local booksellers like the elegant and acclaimed Munro's on Government Street and Bolen Books in the Hillside Centre. Have a listen to this conversation which also delves into the writing process.

Today, we invite you into the captivating world of Erin Keating, a dynamic powerhouse who has climbed the ranks from the film industry to Snapchat, where she led the charge on original mobile shows. Now, Erin is on the cusp of a new chapter, carving out her own path with her raw and honest podcast, "Hotter than Ever." In today's episode, headlined by the empathetic and probing questioning of our host, Reena Friedman Watts, alongside the sagely insights of Wayne Friedman, fondly known as "dad" or "grandpa," we dive deep into Erin's multifaceted journey. Erin bravely shares her inner turmoil over being a corporate spokesman, her craving for self-expression, and her dream of forging a media empire on her terms. As we peel back the layers of Erin's transition from a corporate executive to a champion for authentic storytelling for Gen X women, we confront the conventional self-help narratives. Erin opens up about the personal and professional pivots she's navigated – from her New York artistry and TV executive triumphs to the introspection spurred by a tumultuous marriage and an eye-opening battle with Covid. We'll journey through her bold post-divorce rediscovery and her insightful approach to dating, punctuated with humor, self-compassion, and a rejection of the patterns tied to upbringing and societal pressures. Erin's tale is one of rebirth, a testament to the power of reimagining one's life even in the face of deep-seated challenges. So, join us for a heart-to-heart with Erin Keating, an unfiltered reflection on desire, resilience, and the uncharted waters of self-empowerment. You're listening to "Better Call Daddy," and this is the episode you don't want to miss. Don't forget to like, subscribe, and share as we delve into a story that will leave you inspired, enlightened, and undoubtedly ready to carve out your own path in honesty and self-expression. Erin Keating is an award-winning television development and production executive and single Mom to twin tweens living in Los Angeles. With her eyes on the wider content landscape, Erin created Hotter Than Ever to produce media that reflects the authentic, messy, sexy, funny and inspiring stories of women over forty. Erin's passion for smart, brand-defining original programming has led to zeitgeist-shaping shows like Portlandia, along with the first-ever made-for-mobile scripted series.  Her career has included senior creative roles at Snapchat, Big Beach TV, IFC TV and Magna Global Entertainment.  She climbed the television ladder at BBC America, NBC and Comedy Central. Recent shows created under Erin's watch have included the Emmy-winning James Corden's Next James Corden, the WGA Award winning drama Class of Lies, the WGA Award nominated thriller Breakwater and the NAACP Image Award-nominated Two Sides. Erin also conceived the drama Vida (Starz), produced the documentary Fatherless (Fusion), and executived the hell out of the iconic sketch series Portlandia (which won a Peabody and a bunch of other fancy statues) along with other comedy, dramedy and animated series. Erin grew up in the basement theaters of downtown NYC, where she produced and performed in live comedy shows at venues like The Slipper Room and The Zipper Factory.  She started out as an actor, studying theater at Oberlin College, Meisner technique at Ward Studio, and improvisation at The Second City Training Center in New York. Connect with Erin https://www.hotterthaneverpod.com/ https://www.instagram.com/hotterthaneverpod   Connect with Reena bettercalldaddy.com linkedin.com/in/reenafriedmanwatts twitter.com/reenareena instagram.com/reenafriedmanwatts instagram.com/bettercalldaddypodcast Me and my dad would love to hear from you, Drop us a review, reviews help more people find the show, and let us know what you like and what you'd like us to change, Please share the show with one friend who you think would be helped by the show  ratethispodcast.com/bettercalldaddy podchaser.com/bettercalldaddy Castmagic is the AI tool I use for show notes and podcast title ideas, it has helped save me tons of time. I talked about it in this episode.  Please use my affiliate link if you sign up. https://get.castmagic.io/bettercalldaddy   PodKnow 2024 is happening on Saturday, February 17th, 2024 and will have 10 speakers on everything from podcast growth to monetization and more. Your podcast will definitely benefit from attending and getting all of the valuable information from experts in their fields of podcasting and online marketing. All speakers are successful in their areas! https://nycpodcastnetwork.com/podknow2024-bcd/   Are you a popular podcaster or a rising influencer? Or do you have a great idea for an online business? Then you should know that every great website starts with an awesome domain name. Namecheap offers hundreds of domain extensions, from the traditional dot com to creative extensions for podcasters like dot fm, dot live, or dot space.   Namecheap is the world's 2nd largest domain registrar, with nearly 17 million domains under management and a top web service provider for everything you need to launch an amazing website. Namecheap offers hundreds of domain extensions from the traditional .com to creative extensions like .fm, .live or .space  Namecheap is offering Better Call Daddy listeners 20% off any non-premium domain name for its first year of registration with the code REENA20. The offer cannot be combined with any existing sales but can override any current sale if its discount is less than 20%. The code is valid for all new and existing Namecheap customers. You can register up to 10 domains per account with this code.    To get a domain name with a 20% discount (including .com and 455 other extensions). Go to namecheap.com , search for your desired domain, and use the code REENA20 at checkout.    Better Call Daddy is hosted by Podbean if you are looking to start a podcast of your own you'll need a reliable host https://www.podbean.com/BetterCallDaddy

In the second of the Cannes Conversation Series, we look at script development and how the story gets from the page to the screen. This has been made possible with the support of the Screen Ireland Stakeholder Fund. At Cannes Film Festival last year, WFT Chair Dr. Susan Liddy caught up with producer Annemiek van der Hell at the Writers' Lab networking event. The Writers' Lab is a wonderful initiative created by Elizabeth Kaiden and Nitza Wilon to support female screenwriters over 40. Susan talks with Annemiek about the development of her feature Breakwater, a co-production between The Netherlands, Ireland, and Belgium. Following this, recorded at a live webinar, Scripteditor Gaia Meucci-Astley talks about her career, the industry, and how she works with writers to get their scripts to the best version possible. Utilising her unique background as a film programmer, Gaia shares her tips and tricks in working with your story and characters, to unlock the magic of storytelling. You can contact Gaia about working on your project at https://www.gaiascripteditor.com/ https://wft.ie

This week, Kara and Liza recap the episode “Breakwater” (Season 24, Episode 5). Plus, they discuss the Chicago Park District lifeguard sexual abuse scandal and the Paul Hickson rape cases.SOURCES:Cook County Sheriff's OfficeWBEZ 1WBEZ 2WBEZ 3WBEZ 4WBEZ 5WBEZ 6WBEZ 7WBEZ 8Chicago Sun-Times 1Chicago Sun-Times 2Chicago Sun-Times 3Chicago Sun-Times 4Chicago Sun-Times 5The IndependentThe HeraldWikipedia - Paul HicksonThe StatesmanWHAT WOULD SISTER PEG DO:Safe4AthletesNext week's episode will be “Baby Killer” (Season 2, Episode 5).See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

An Unexpected Road to Religion and Meaning  Breakwater Festival 2023 Paths, People & Places Posted here: https://www.youtube.com/@flowinthedarkproductions6449     Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/eex6RuVC https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Today we are chatting with writer/director James Rowe about his new film BREAKWATER. BREAKWATER stars Dermot Mulroney and Darren Mann. It's a fantastic thriller with lots of twists and turns. Hosted by: Andrew Lamping and Jeff Stolhand Produced by: Melody Lopez Original Theme Music by: Stephen D. Bennett --- Send in a voice message: https://podcasters.spotify.com/pod/show/filmmakermixer/message

On CinemAddicts episode 221, we review the features The Mental State (2:12), A Creature Was Stirring (7:58), Breakwater (14:58), Freud's Last Session (23:11), and The Great Silence (31:24).For December's Patreon episode, we spotlight 1983 with reviews of The Keep and Eureka.Use our Amazon movie links or SiteStripe for your purchases to support CinemAddicts (we receive a slight commission)!**Check out our CinemAddicts podcast feed for previous episodes on Acast: https://shows.acast.com/cinemaddicts1. Subscribe to our CinemAddicts YouTube Channel.2. Like Our CinemAddicts Facebook Page3. Join our CinemAddicts Facebook Group for daily movie recommendations! 4. Questions/comments on CinemAddicts email Greg Srisavasdi at info@findyourfilm.com.5. Find CinemAddicts recaps and coverage on our website Find Your Film.6. Contact Bruce Purkey for some What's in the Box recommendations: brucepurkey@gmail.com7. Eric Holmes can be reached at hamslime@gmail.com and on X. 8. Anderson Cowan's latest project is Loaded for Bear: The Documentary. For info and support: https://loadedforbeardoc.com/ Hosted on Acast. See acast.com/privacy for more information.

Willow Kean does an winning monologue in studio, we hear from author Donna Morrissey, and publishers from three different publishing houses, Glenn Day from Boulder Books, Rebecca Rose from Breakwater Books, and Jerry Cranford from Flanker Press, join Krissy in studio. Recommended books from publishers include: Glenn Day from Boulder books tells us about their latest guide book "Beaches of Newfoundland" by Carla Smith Krachun. He also recommends Hidden Nova Scotia, a children's book called Walter & Seymore: Let's Play by Kim Osbourne, and The Grounds Café cook book. Then, Rebecca from Breakwater recommends Impressions of Newfoundland by Ting Ting Chen, Suliewey by Mi'sel Joe and Sheila O'Neill, Five for Forteau by Kevin Major, and A Company of Rogues by Trudy J. Morgan-Cole. For children's books, Rebecca recommends IsThisAnOlogy? by Amanda Dorothy Jean Bulman, and The Ewe Who Knew Who Knit You by Cara Kansala. Last, Jerry Cranford from Flanker Press recommends The World Search of Newfoundland and Labrador - Volume 2 - by Nick Cranford, Much More Than Police by Terry Carlson, Away From My Island by Gary Collins, We'd Rather Fight Than Eat by Jay McGrath, and The River Murder by Patrick J Collins.

Kristen K. Ciombor, MD, MSCI, an assistant professor in the Division of Hematology/Oncology in the Department of Medicine at the Vanderbilt University Medical Center, recently spoke at an Around the Practice discussion regarding updates in the world of metastatic colorectal cancer (CRC). In this episode of the ONCOLOGY® On the Go Podcast, she discusses treatment updates, molecular testing options, and emerging targets in CRC. Ciombor also highlighted ongoing research in the space, including the phase 3 BREAKWATER (NCT04607421)1 trial and the phase 3 MOUNTAINEER-03 (NCT05253651)2 trial. She also discussed some of the most important presentations from the 2023 European Society for Medical Oncology (ESMO) Congress, including those covering the phase 2 MOUNTAINEER study (NCT03043313)3 and the phase 3 KEYNOTE-811 trial (NCT03615326).4 Additionally, she spoke about her work in the phase 2 ECOG-ACRIN trial (NCT04751370) assessing neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high or mismatch repair deficient rectal cancer.5 “I'm hoping that we see more treatment options for patients [and that] we identify more patient subtypes that we can target and find actionable alterations for,” Ciombor said. References 1. Kopetz S, Grothey A, Yaeger R, et al. BREAKWATER: randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). J Clin Oncol. Published online May 28, 2021. doi:10.1200/jco.2021.39.15_suppl.tps3619 2. Bekaii-Saab TS, Van Cutsem E, Tabernero J, et al. MOUNTAINEER-03: phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress. J Clin Oncol. Published online January 24, 2023. doi:10.1200/jco.2023.41.4_suppl.tps261 3. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. Published online May 24, 2023. doi:10.1016/S1470-2045(23)00150-X  4. Janjigian YY, Kawazoe A, Bai Y, et al. embrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study. Ann Oncol. 2023;34(suppl 2):S851-S852. doi:10.1016/j.annonc.2023.09.1424 5. Ciombor KK, Hong SC, Eng C, et al. EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors. J Clin Oncol. Published online June 2, 2022. doi:10.1200/jco.2022.40.16_suppl.tps3644

Upcoming TLC Events Breakwater Festival Mannheim Germany October 27-29 2023 Event Details and Tickets: https://buytickets.at/breakwater/935800   T-shirts: https://buytickets.at/breakwater/store Discord: tinyurl.com/BreakwaterDiscord   Festival Email: contact.breakwater@gmail.com  Flyer https://bit.ly/breakwaterfestival2023  Convivium 2023: Poetry as Perception, November 17-18, Hector, AR https://events.eventzilla.net/e/convivium-2023-poetry-as-perception-2138588315 Join this channel to get access to perks: https://www.youtube.com/channel/UCGsDIP_K6J6VSTqlq-9IPlg/join   Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/nZADRwgy https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640

Breakwaters ease the impact of large waves during storms, reducing shoreline erosion and damage. We learn about efforts to improve a Milwaukee breakwater, bolstering protection for the Harbor District.

This week's episode is a FUN one with Erin Keating who talks about her tips on being "Hotter Than Ever."  Erin tells the story about how she blew up her life at age 50 and started to reinvent herself to become a more authentic version of myself TODAY (rather just living in the results of the goals she had for myself and my life 20 years ago).  She also describes her unconventional dating "Rumspringa" the year following my separation (her year to explore and 'sow her wild oats'), and 4 things you can do to be Hotter than Ever.  Erin Keating is an award-winning television development and production executive and single Mom to twin tweens living in Los Angeles. Her podcast Hotter Than Ever reflects the authentic, messy, sexy, funny and inspiring stories of women over forty. Erin's passion for smart, brand-defining original programming has led to zeitgeist-shaping shows like Portlandia, along with the first-ever made-for-mobile scripted series.  Her career has included senior creative roles at Snapchat, Big Beach TV, IFC TV and Magna Global Entertainment.  She climbed the television ladder at BBC America, NBC and Comedy Central. Recent shows created under Erin's watch have included the Emmy-winning James Corden's Next James Corden, the WGA Award winning drama Class of Lies, the WGA Award nominated thriller Breakwater and the NAACP Image Award-nominated Two Sides. Erin also conceived the drama Vida (Starz), produced the documentary Fatherless (Fusion), and executived the hell out of the iconic sketch series Portlandia (which won a Peabody and a bunch of other fancy statues) along with other comedy, dramedy and animated series.  Erin grew up in the basement theaters of downtown NYC, where she produced and performed in live comedy shows at venues like The Slipper Room and The Zipper Factory.  She started out as an actor, studying theater at Oberlin College, Meisner technique at Ward Studio, and improvisation at The Second City Training Center in New York. Download this episode, share it on social, and sign up for our free newsletter by filling out any contact form on our site (www.smartdatingacademy.com).  Follow us on Instagram as well @smartdatingacademy! Fill out our podcast listener survey by putting this link into your browser:  https://www.smartdatingacademy.com/survey Follow us on Instagram at @smartdatingacademy Schedule your consultation with us here!   We are on a waiting list, and would love to help you!  https://www.smartdatingacademy.com/11-coaching/coaching-call-with-bela

The fellas drop in CoLab Public House in Vista, CA. The CoLab is a craft beer lovers paradise! No need to brew hoo here, you've got 3 solid breweries Breakwater, Barrel n Stave and Laguna Beer Co. And for the Wine lover you have Propaganda Wine Co. And did we mention Baby's Badass Burgers? Join us on this amazing episode! Special guests include Chris from Barrel and Stave and Joe from Propaganda! Cheers Everyone! Support the showHop Con 2023

The ACP team up with Tom Curry and look back on the last 8 years of the podcast. Books and moments are revisited, recommendations are laid down and tons of fun is had as the pod prepares for the next chunk of comic making years! Great stuff to check out this week - Tom Curry, Viz, Helen McCarthy, Leamington Comic Con, OK Comics, Mark Millar, Pat Mills, Awesome Comics, Infinite Kung Fu, Avery Hill, Follow Me In, Katriona Chapman, Breakwater, Porcelain, Snake Claws, Eternal, Outer Darkness, WIP Comics Anthology, Bette Noir, Andrew Clemson, Knave of Hearts, Sarah Webb, ACP recommends, Mobile Suit Gundam: The Origin, Jeff, Rising Sand, Dragons Claws, EJunkie Guardians of Pain, Jamie Me, B:Mecha

7 - 07 - 23 BLAKES NEVER ENDING PTOWN BREAKWATER WALK by Maine's Coast 93.1

Here are all the links for the festival:  Event Details and Tickets: https://buytickets.at/breakwater/935800     T-shirts: https://buytickets.at/breakwater/store  Discord: tinyurl.com/BreakwaterDiscord         Festival Email: contact.breakwater@gmail.com   Flyer https://bit.ly/breakwaterfestival2023   July Washington DC Event with Michael Martin and Spencer Klavan https://www.eventbrite.com/e/christ-and-community-in-the-modern-age-tickets-608591853617 Paul Vander Klay clips channel https://www.youtube.com/channel/UCX0jIcadtoxELSwehCh5QTg Bridges of Meaning Discord https://discord.gg/rpf3zatJ https://www.meetup.com/sacramento-estuary/ My Substack https://paulvanderklay.substack.com/ Estuary Hub Link https://www.estuaryhub.com/ If you want to schedule a one-on-one conversation check here. https://paulvanderklay.me/2019/08/06/converzations-with-pvk/ There is a video version of this podcast on YouTube at http://www.youtube.com/paulvanderklay To listen to this on ITunes https://itunes.apple.com/us/podcast/paul-vanderklays-podcast/id1394314333  If you need the RSS feed for your podcast player https://paulvanderklay.podbean.com/feed/  All Amazon links here are part of the Amazon Affiliate Program. Amazon pays me a small commission at no additional cost to you if you buy through one of the product links here. This is is one (free to you) way to support my videos.  https://paypal.me/paulvanderklay Blockchain backup on Lbry https://odysee.com/@paulvanderklay https://www.patreon.com/paulvanderklay Paul's Church Content at Living Stones Channel https://www.youtube.com/channel/UCh7bdktIALZ9Nq41oVCvW-A To support Paul's work by supporting his church give here. https://tithe.ly/give?c=2160640  

This week in North County San Diego…Cassidy explored an awesome BBQ joint in Fallbrook among many All-Star games, Chris hit up one of the best Happy Hours in all of North County (and the Pony Room), and we had some new brews. Also, Lake Hodges is back open, Breakwater is closing a location, the Airport is getting some new spots, and Hader listens to himself when pitching. Enjoy! 

Celeste's billionaire mother founded Breakwater as a place to escape the disasters of the late 21st century. Using a gene modification, its population has been able to stop aging. The modification, however, results in long-term memory loss, forcing Breakwater to rely on new technology to store and reload memories. Celeste starts to suspect something is amiss with the system as the annual celebration of the community's founding approaches. CONNECT WITH US makeshiftstories@gmail.com SHARE THE PODCAST If you liked this episode, tell your friends to head over to Apple Podcasts and subscribe. CREDITS Written by Alan V Hare. Read by Kathleen Connolly. Opening and closing were composed and created by Matthew Erdmann. Produced by Makeshift Studios Makeshift Stories is released under a creative commons non-commercial attribution, no derivative license. This means you are free to share our stories just remember to credit us.

Welcome to the realm of Serein, a world of gods and goddesses, of leylines and magic, of friends and foes, and of adventure! Follow the tale of the Secondary Heroes: an unlikely rag-tag group of not-quite-knighs, bastards, reckless mages, and rogues who ultimately hold the fate of all in their hands.

 This is an episode of a series from our previous project, the Level 1 Podcast, re-released here on the Diceology feed. Please note that the audio quality is a little lower, and that we make reference to upcoming events, and email accounts/social media accounts that are no longer active and/or relevant.

Wyatt Fields is the owner and pitmaster of Breakwater BBQ in El Granada, California .After five jam packed years of full-service, catering for weddings, and some of the biggest tech companies in the Bay Area and everything in between, Wyatt decided to take the next step in his journey and open a small store front in the coastal town of El Granada, California right before the start of the global pandemic of 2020. Located right where the Princeton Harbor Jetty meets the Coast Highway, hence the name Breakwater.  It's a special location to Wyatt  where he went to elementary school , formed lifelong friendships, and stood up on his first wave. Wyatt brings his own craft of traditional style of Texas and Carolina smoked barbecue to his hometown, which has always been his goal. I really enjoyed catching up with Wyatt on location and enjoyed talking to him about his origins and all things barbecue!Breakwater Barbecuehttps://www.breakwaterbbq.comShow Noteshttps://www.foodoriginspodcast.com/podcast-episode-25Support the show

Shereen recaps some events in Palestine in 2022 that led to it being the deadliest year in the West Bank in decades. She also discusses Israel's far-right government and the recently-appointed ultranationalist ministers who will only take it further in that direction.See omnystudio.com/listener for privacy information.

In this episode we talk to two Coasties who have started something very special that could help out a lot of shipmates.  We also cover some new swag and some merch on the horizon. --- Send in a voice message: https://anchor.fm/thedisgruntledsailor/message Support this podcast: https://anchor.fm/thedisgruntledsailor/support

Korea24 – 2022.12.08 (Thursday) News Briefing: The unionized truckers strike entered its 15th day as the government expanded its return to work orders to the steel and petrochemical industries. (Koo Hee-jin) In-Depth News Analysis: Last week, President Yoon Suk Yeol called for China to help dissuade North Korea from further banned nuclear weapons development. He also called on Beijing to fulfill its responsibilities as a permanent member of the U.N. Security Council. This comes as the prospect of a seventh nuclear test by the North remains. To discuss President Yoon’s comments and the broader China-North Korea relationship, Professor Robert Kelly from Pusan National University joins us on the line. Korea Trending with Diane Yoo: 1. Analysis of the 2023 CSAT, aka Suneung, was released on Thursday, which showed that the Korean language section was easier than last year, but mathematics was more difficult. (올해 수능 만점자는 3명‥"국어 쉽고 수학은 만점자 급감") 2. A 63-year-old man has been caught by the police for the illicit capture and sale of wild animals, with more than 4,000 snakes in possession. (뱀 4000마리를 밀렵꾼 1명이…오소리·고라니도 냉동 보관) 3. North Korea’s state media belatedly aired South Korea’s football match against Brazil at the Qatar 2022 World Cup on Wednesday. (북한TV, 한국-브라질전 녹화 중계… 손흥민·황희찬 경력도 소개) Explore Korea: Travel Explorer Hannah Roberts joins us in the studio to tell us about the Seoul Urban Life Museum, which chronicles how life in the capital has changed in modern times. We also discuss a current special exhibition, called “Residential Life in Seoul” looking specifically at how homes have changed. Morning Edition Preview with Richard Larkin: - Tomorrow’s Korea Herald features a report by Lee Yoon-seo on the growing number of people taking personal color tests to find out which color best suits them. - In tomorrow’s Korea Times, Park Han-sol reports on "Fermented Flower", an installation produced by Korean artist duo Breakwater, that visualizes the history of labor migration in Asia in the 19th century.

Narrator: Abbe Opher